Actinium Pharmaceuticals, Inc. (ATNM)

US — Healthcare Sector
Peers: INKT  AFMD  IMGN  ADAP  SGMO  RIGL  FBIO  RVPH  CTIC  OCUP  ANVS  SAVA  AXSM  MCRB  RVPHW  EYEN  CGTX  RNAZ  KOD  EXEL  TGTX  VKTX  MDGL  BTAI 

Automate Your Wheel Strategy on ATNM

With Tiblio's Option Bot, you can configure your own wheel strategy including ATNM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ATNM
  • Rev/Share 0.0
  • Book/Share 0.8236
  • PB 1.8698
  • Debt/Equity 0.0558
  • CurrentRatio 9.3468
  • ROIC -0.7913

 

  • MktCap 48041686.0
  • FreeCF/Share -1.0666
  • PFCF -1.4439
  • PE -1.0556
  • Debt/Assets 0.0209
  • DivYield 0
  • ROE -1.2957

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 3
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Shareholders of Actinium Pharmaceuticals, Inc. (ATNM): Protect Your Rights Before May 27, 2025 - Contact Levi & Korsinsky
ATNM
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 27, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=150393&wire=1&utm_campaign=21 or contact Joseph E. Levi, Esq.

Read More
image for news Shareholders of Actinium Pharmaceuticals, Inc. (ATNM): Protect Your Rights Before May 27, 2025 - Contact Levi & Korsinsky
Levi & Korsinsky Urges Actinium (ATNM) Shareholders to Act Before Lead Plaintiff Deadline May 27, 2025
ATNM
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 27, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=150356&wire=1&utm_campaign=19 or contact Joseph E. Levi, Esq.

Read More
image for news Levi & Korsinsky Urges Actinium (ATNM) Shareholders to Act Before Lead Plaintiff Deadline May 27, 2025
ATNM DEADLINE TODAY: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important May 27 Deadline in Securities Class Action - ATNM
ATNM
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Rosen Law Firm: WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) between October 31, 2022 and August 2, 2024, both dates inclusive (the "Class Period"), of the important May 27, 2025 lead plaintiff deadline. SO WHAT: If you purchased Actinium securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Read More
image for news ATNM DEADLINE TODAY: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important May 27 Deadline in Securities Class Action - ATNM
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. Investors - Lead Plaintiff Deadline May 27, 2025
ATNM
Published: May 26, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 26, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=150254&wire=1&utm_campaign=7 or contact Joseph E. Levi, Esq.

Read More
image for news ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. Investors - Lead Plaintiff Deadline May 27, 2025
Lost Money on Actinium Pharmaceuticals, Inc. (ATNM)? Urged to Join Class Action Before May 27, 2025 - Contact Levi & Korsinsky
ATNM
Published: May 26, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 26, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=150240&wire=1&utm_campaign=22 or contact Joseph E. Levi, Esq.

Read More
image for news Lost Money on Actinium Pharmaceuticals, Inc. (ATNM)? Urged to Join Class Action Before May 27, 2025 - Contact Levi & Korsinsky
ATNM Deadline: ATNM Investors with Losses in Excess of $100K Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit
ATNM
Published: May 26, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , May 26, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022 and August 2, 2024, both dates inclusive (the "Class Period"), of the important May 27, 2025 lead plaintiff deadline. So what: If you purchased Actinium securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Read More
image for news ATNM Deadline: ATNM Investors with Losses in Excess of $100K Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit
Class Action Lawsuit Filed: Actinium Pharmaceuticals, Inc. (ATNM) - Join by May 27, 2025 - Contact Levi & Korsinsky
ATNM
Published: May 26, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 26, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=150203&wire=1&utm_campaign=8 or contact Joseph E. Levi, Esq.

Read More
image for news Class Action Lawsuit Filed: Actinium Pharmaceuticals, Inc. (ATNM) - Join by May 27, 2025 - Contact Levi & Korsinsky
FINAL REMINDER ATNM DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Actinium Pharmaceuticals, Inc. Investors to Participate in the Class Action Lawsuit
ATNM
Published: May 26, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / May 26, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE:ATNM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Actinium securities between March 31, 2022 and August 2, 2024, both dates inclusive (the "Class Period").

Read More
image for news FINAL REMINDER ATNM DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Actinium Pharmaceuticals, Inc. Investors to Participate in the Class Action Lawsuit
Lost Money on Actinium Pharmaceuticals, Inc. (ATNM)? Contact Levi & Korsinsky to Join Class Action Before May 27, 2025
ATNM
Published: May 25, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 25, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=150179&wire=1&utm_campaign=20 or contact Joseph E. Levi, Esq.

Read More
image for news Lost Money on Actinium Pharmaceuticals, Inc. (ATNM)? Contact Levi & Korsinsky to Join Class Action Before May 27, 2025
ATNM DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 27 Deadline in Securities Class Action – ATNM
ATNM
Published: May 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, May 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022 and August 2, 2024, both dates inclusive (the “Class Period”), of the important May 27, 2025 lead plaintiff deadline.

Read More
image for news ATNM DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 27 Deadline in Securities Class Action – ATNM
ATNM Deadline: Rosen Law Firm Urges Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
ATNM
Published: May 23, 2025 by: Business Wire
Sentiment: Neutral

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022, and August 2, 2024. Actinium describes itself as a “late-stage biopharmaceutical company that develops targeted radiotherapies.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegation.

Read More
image for news ATNM Deadline: Rosen Law Firm Urges Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) Over Securities Violations - Contact Levi & Korsinsky Today
ATNM
Published: May 23, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 23, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=149907&wire=1&utm_campaign=29 or contact Joseph E. Levi, Esq.

Read More
image for news Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) Over Securities Violations - Contact Levi & Korsinsky Today
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - May 27, 2025 Deadline to Join - Contact Levi & Korsinsky
ATNM
Published: May 23, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , May 23, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were adversely affected by alleged securities fraud between October 31, 2022 and August 2, 2024.

Read More
image for news Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - May 27, 2025 Deadline to Join - Contact Levi & Korsinsky
May 27, 2025 Deadline: Join Class Action Lawsuit Against Actinium Pharmaceuticals, Inc. (ATNM) - Contact Levi & Korsinsky
ATNM
Published: May 23, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 23, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=149872&wire=1&utm_campaign=6 or contact Joseph E. Levi, Esq.

Read More
image for news May 27, 2025 Deadline: Join Class Action Lawsuit Against Actinium Pharmaceuticals, Inc. (ATNM) - Contact Levi & Korsinsky
Securities Fraud Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) – Levi & Korsinsky Reminds Investors of May 27, 2025
ATNM
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 22, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=149837&wire=1&utm_campaign=27 or contact Joseph E. Levi, Esq.

Read More
image for news Securities Fraud Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) – Levi & Korsinsky Reminds Investors of May 27, 2025
ATNM ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Actinium Pharmaceuticals, Inc. - May 27, 2025 Deadline
ATNM
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 22, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=149817&wire=1&utm_campaign=26 or contact Joseph E. Levi, Esq.

Read More
image for news ATNM ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Actinium Pharmaceuticals, Inc. - May 27, 2025 Deadline
Shareholders that lost money on Actinium Pharmaceuticals, Inc. (ATNM) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More
ATNM
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit.

Read More
image for news Shareholders that lost money on Actinium Pharmaceuticals, Inc. (ATNM) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More
Investors Urged to Contact Levi & Korsinsky for Information Before May 27, 2025 - Actinium Pharmaceuticals, Inc. (ATNM)
ATNM
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 22, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=149786&wire=1&utm_campaign=5 or contact Joseph E. Levi, Esq.

Read More
image for news Investors Urged to Contact Levi & Korsinsky for Information Before May 27, 2025 - Actinium Pharmaceuticals, Inc. (ATNM)
Lost Money on Actinium Pharmaceuticals, Inc. (ATNM)? Contact Levi & Korsinsky Before May 27, 2025 to Join Class Action
ATNM
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 22, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=149767&wire=1&utm_campaign=12 or contact Joseph E. Levi, Esq.

Read More
image for news Lost Money on Actinium Pharmaceuticals, Inc. (ATNM)? Contact Levi & Korsinsky Before May 27, 2025 to Join Class Action
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
ATNM
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE: ATNM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
Lost Money on Actinium Pharmaceuticals, Inc. (ATNM)? Contact Levi & Korsinsky to Join Class Action Before May 27, 2025
ATNM
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 22, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=149713&wire=1&utm_campaign=20 or contact Joseph E. Levi, Esq.

Read More
image for news Lost Money on Actinium Pharmaceuticals, Inc. (ATNM)? Contact Levi & Korsinsky to Join Class Action Before May 27, 2025
ATNM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Actinium Pharmaceuticals, Inc. to Contact the Firm Today!
ATNM
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE:ATNM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Actinium securities between March 31, 2022 and August 2, 2024, both dates inclusive (the "Class Period").

Read More
image for news ATNM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Actinium Pharmaceuticals, Inc. to Contact the Firm Today!
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM
ATNM
Published: May 22, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , May 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Shareholders who purchased shares of ATNM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Read More
image for news The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) Over Securities Violations - Contact Levi & Korsinsky Today
ATNM
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 22, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=149698&wire=1&utm_campaign=29 or contact Joseph E. Levi, Esq.

Read More
image for news Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) Over Securities Violations - Contact Levi & Korsinsky Today
Class Action Alert: Levi & Korsinsky Reminds Actinium (ATNM) Investors of May 27, 2025 Deadline
ATNM
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=149680&wire=1&utm_campaign=17 or contact Joseph E. Levi, Esq.

Read More
image for news Class Action Alert: Levi & Korsinsky Reminds Actinium (ATNM) Investors of May 27, 2025 Deadline
Securities Lawsuit Alert: Actinium Pharmaceuticals, Inc. (ATNM) - Contact Levi & Korsinsky Before May 27, 2025
ATNM
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 21, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=149660&wire=1&utm_campaign=3 or contact Joseph E. Levi, Esq.

Read More
image for news Securities Lawsuit Alert: Actinium Pharmaceuticals, Inc. (ATNM) - Contact Levi & Korsinsky Before May 27, 2025
Shareholders of Actinium Pharmaceuticals, Inc. (ATNM): Protect Your Rights Before May 27, 2025 Contact Levi & Korsinsky
ATNM
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 21, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=149597&wire=1&utm_campaign=21 or contact Joseph E. Levi, Esq.

Read More
image for news Shareholders of Actinium Pharmaceuticals, Inc. (ATNM): Protect Your Rights Before May 27, 2025 Contact Levi & Korsinsky
Class Action Alert: Levi & Korsinsky Reminds Actinium (ATNM) Investors of May 27, 2025 Deadline
ATNM
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 21, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=149580&wire=1&utm_campaign=17 or contact Joseph E. Levi, Esq.

Read More
image for news Class Action Alert: Levi & Korsinsky Reminds Actinium (ATNM) Investors of May 27, 2025 Deadline
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
ATNM
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE:ATNM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. Investors - Lead Plaintiff Deadline May 27, 2025
ATNM
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 21, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=149493&wire=1&utm_campaign=7 or contact Joseph E. Levi, Esq.

Read More
image for news ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. Investors - Lead Plaintiff Deadline May 27, 2025

About Actinium Pharmaceuticals, Inc. (ATNM)

  • IPO Date 2012-12-27
  • Website https://www.actiniumpharma.com
  • Industry Biotechnology
  • CEO Mr. Sandesh C. Seth M.B.A., M.S.
  • Employees 31

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.